Tritanrix HepB (diphtheria (D), tetanus (T), pertussis (whole cell) (Pw) and hepatitis B (rDNA) (HBV) vaccine (adsorbed))
- Region
- 🇪🇺 EU
- Active substance
- diphtheria (D), tetanus (T), pertussis (whole cell) (Pw) and hepatitis B (rDNA) (HBV) vaccine (adsorbed)
- Company
- GlaxoSmithKline Biologicals S.A.
- Status
- Lapsed
- Therapeutic area
- Hepatitis B; Tetanus; Immunization; Whooping Cough; Diphtheria
- EU approval
- Fri 19 Jul 1996
- Application
- EMEA/H/C/000093
- ATC
- J07CA05
- Official record
- www.ema.europa.eu
Indication
Tritanrix HepB is indicated for active immunisation against diphtheria, tetanus, pertussis and hepatitis B (HBV) in infants from six weeks onwards (see section 4.2).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Infanrix Hexa Authorised · GlaxoSmithKline Biologicals S.A.
- 🇪🇺 Infanrix Penta Lapsed · GlaxoSmithKline Biologicals S.A.
Follow Tritanrix HepB
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.